Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

Psychiatry Research

Volumn 88, Issue 2, 1999, Pages 107-117

  Peuskens, Joseph ^a   Bech, Per ^b   Möller, Hans Jürgen ^c   Bale, Robert ^d   Fleurot, Odile ^e   Rein, Werner ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HILLERØD HOSPITAL   (Denmark)

^c UNIVERSITY OF MUNICH   (Germany)

^d QUEEN MARY S HOSPITAL   (United Kingdom)

^e SANOFI   (France)

Author keywords

Acute exacerbations; Amisulpride; Atypical antipsychotic; Efficacy; Risperidone; Schizophrenia; Tolerability

Indexed keywords

AMISULPRIDE; RISPERIDONE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; VOMITING; WEIGHT GAIN;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 0032707282     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(99)00075-X     Document Type: Article

References (41)

1. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). 1994;American Psychiatric Association, Washington DC.
2. Arvanitis L.A., Miller B.G. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry. 42:1997;233-246.
3. Baldessarini R.J., Cole J.O., Davis J.M. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. American Journal of Psychiatry. 137:1980;1163-1172.
4. Barnes T.R.E. A rating scale for drug-induced akathisia. British Journal of Psychiatry. 154:1989;672-673.
5. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124:1996;159-167.
6. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;118-123.
7. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. American Journal of Psychiatry. 155:1998;499-504.
8. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry. 166:1995;68-72.
9. Carman J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. International Clinical Psychopharmacology. 10:1995;207-213.
10. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology. 13:1993;25-40.
11. Davies L.M., Drummond M.F. Economics and schizophrenia: the real cost. British Journal of Psychiatry. 165(Suppl 25):1994;18-21.
12. Farde L., Nordström A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side-effects. Archives of General Psychiatry. 49:1992;538-544.
13. Hoyberg O.J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielsen M., Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica. 88:1993;395-402.
14. Huttunen M., Piepponen T., Rantanen H., Larmo I., Nyholm R., Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatrica Scandinavica. 91:1995;271-277.
15. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 13:1987;261-276.
16. Loo H., Poirier-Littre M.-F., Théron M., Rein W., Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry. 170:1997;18-22.
17. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. 151:1994;825-835.
18. Möller H.-J. Neuroleptic treatment of negative symptoms in schizophrenic patients: efficacy problems and methodological difficulties. European Neuropsychopharmacology. 3:1993;1-11.
19. Möller H.-J., Boyer P., Fleurot O., Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology. 132:1997;396-401.
20. CGI, Clinical Global Impression. Guy W. ECDEU Assessment Manual of Psychopharmacology Rev. 1976;217-222 NIMH, Rockville, Maryland.
21. AIMS, Abnormal Involuntary Movement Scale. Guy W. ECDEU Assessment Manual of Psychopharmacology Rev. 1976;534-537 NIMH, Rockville, Maryland.
22. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports. 10:1962;799-812.
23. Oyewumi L.K., Lapierre Y.D., Gray R., Batth S., Gelfand R. Abnormal involuntary movements in patients on long-acting neuroleptics. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 7:1983;719-723.
24. Paillère-Martinot M.L., Lecrubier Y., Martinot J.L., Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. American Journal of Psychiatry. 152:1995;130-133.
25. Perrault G.H., Depoortere R., Morel E., Sanger D.J., Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics. 280:1997;73-82.
26. Peuskens J. Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind parallel-group comparative study versus haloperidol. British Journal of Psychiatry. 166:1995;712-726.
27. Puech A., Fleurot O., Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute exacerbations of schizophrenia: a dose-ranging study versus haloperidol. Acta Psychiatrica Scandinavica. 98:1998;65-72.
28. Regier D.A., Boyd J.H., Burke J.D., Rae D.S., Myers J.K., Kramer M., Robins L.N., George L.K., Karno M., Locke B.Z. One month prevalence of mental disorders in the US: based on five epidemiological catchment area (ECA) sites. Archives of General Psychiatry. 45:1988;977-986.
29. Rupp A., Keith S.J. The costs of schizophrenia: assessing the burden. Psychiatric Clinics of North America. 16:1993;413-423.
30. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., Oblin A., Gonon F., Carter C., Benavides J., Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics. 280:1997;83-97.
31. Schooler N.R. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatrica Scandinavica. 89(Suppl. 380):1994;21-26.
32. Shepherd M., Watt D., Falloon J., Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine Monograph Supplement. 15:1989;1-46.
33. Simpson G., Angus J.A. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 45(Suppl. 212):1970;11-19.
34. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G.G. Quetiapine in patients with schizophrenia. Archives of General Psychiatry. 54:1997;549-557.
35. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
36. Tarsey D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clinical Neuropharmacology. 6(Suppl. 1):1983;S9-S26.
37. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology. 17:1997;407-418.
38. Van Kammen D.P., McEvoy K.P., Targum S.D., Kardatzke D., Seebree T.B. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology. 124:1996;168-175.
39. Van Putten T., May P.R.A. Subjective response as a predictor of outcome in pharmacotherapy. Archives of General Psychiatry. 35:1978;477-480.
40. Wetzel H., Gründer G., Hillert A., Philipp M., Gattaz W.F., Sauer H., Adler G., Schröder J., Rein W., Benkert O. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double blind controlled study comparing a selective D2-like antagonist to a mixed D1-D2-like antagonist. Psychopharmacology. 137:1998;223-232.
41. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J., Sebree T.B., Wallin B.A., Kashkin K.B. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry. 154:1997;782-791.